AC-430

DB12535InvestigationalSmall molecule

AC430 has been investigated for the treatment of Rheumatoid Arthritis.

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK2
Curator reviewed
Formula / weight: C₁₉H₁₆FN₅O · 349.369 g/mol (avg)
Code names: AC-430

Resolves to

Compound

Structure

InChIKeyDCRWIATZWHLIPN-UHFFFAOYSA-NSMILESCC1=CC(NC2=NC(=NC3=CC=CC=C23)C(O)C2=CC=C(F)C=C2)=NN1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with AC-430, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.